CRSP - CRISPR Therapeutics AG
IEX Last Trade
40.07
-0.030 -0.075%
Share volume: 54,570
Last Updated: Fri 27 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$40.10
-0.03
-0.07%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-01 | 2023-02-21 | 2023-05-08 | 2023-08-07 | 2023-11-06 | 2024-02-21 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 2.463 B | 2.353 B | 2.243 B | 2.244 B | 2.197 B | 2.087 B | 2.230 B | 2.439 B | |
| Current Assets | 2.107 B | 1.933 B | 1.853 B | 1.908 B | 1.860 B | 1.761 B | 1.908 B | 2.120 B | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 41.651 M | 36.679 M | 37.708 M | 24.796 M | 21.469 M | 20.760 M | 14.386 M | 11.499 M | |
| Short Term Investments | 41.651 M | 36.679 M | 37.708 M | 24.796 M | 21.469 M | 20.760 M | 14.386 M | 11.499 M | |
| Total Receivables | 66.000 K | 49.000 K | 0.000 | 0.000 | 70.000 M | 0.000 | 200.000 M | 0.000 | |
| Current Cash | 2.065 B | 1.896 B | 1.815 B | 1.883 B | 1.768 B | 1.740 B | 1.694 B | 2.108 B | |
| Total Non-current Assets | 356.307 M | 420.653 M | 390.031 M | 336.398 M | 337.442 M | 326.244 M | 321.493 M | 319.393 M | |
| Property Plant Equipment | 165.194 M | 166.110 M | 163.634 M | 162.198 M | 159.172 M | 156.122 M | 151.945 M | 147.253 M | |
| Other Assets | 3.760 M | 3.682 M | 4.640 M | 2.760 M | 2.175 M | 2.047 M | 1.975 M | 9.368 M | |
| Intangible Assets | 98.000 K | 84.000 K | 71.000 K | 57.000 K | 43.000 K | 30.000 K | 16.000 K | 2.000 K | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.463 B | 2.353 B | 2.243 B | 2.244 B | 2.197 B | 2.087 B | 2.230 B | 2.439 B | |
| Total liabilities | 372.532 M | 399.402 M | 367.578 M | 389.468 M | 380.986 M | 359.036 M | 346.768 M | 355.081 M | |
| Total current liabilities | 119.957 M | 150.870 M | 121.107 M | 146.794 M | 132.837 M | 111.234 M | 108.791 M | 118.990 M | |
| Accounts Payable | 25.244 M | 32.114 M | 27.428 M | 45.153 M | 27.588 M | 26.152 M | 38.147 M | 16.463 M | |
| Other liabilities | 18.415 M | 17.637 M | 18.292 M | 18.122 M | 17.807 M | 21.217 M | 14.970 M | 17.156 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 18.415 M | 17.637 M | 18.292 M | 18.122 M | 17.807 M | 21.217 M | 14.970 M | 17.156 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 2.091 B | 1.954 B | 1.875 B | 1.855 B | 1.816 B | 1.728 B | 1.883 B | 2.084 B | |
| Common stock | 77.513 M | 78.022 M | 78.353 M | 78.677 M | 79.091 M | 79.414 M | 79.702 M | 81.795 M | |
| Retained earnings | -560.966 M | -735.515 M | -846.090 M | -899.155 M | -976.895 M | -1.089 B | -999.700 M | -1.116 B |